FindTrial
Sign In

Proteomic study of nasopharyngeal carcinoma specific antigens

Proteomic study of nasopharyngeal carcinoma specific marker antigens

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-BOR-17011912
Enrollment
Unknown
Registered
2017-07-08
Start date
2017-07-01
Completion date
Unknown
Last updated
2017-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nasopharyngeal carcinoma

Interventions

nasopharyngeal carcinoma group: biopsy specimens collecting
Control:biopsy specimens collecting

Sponsors

Shenzhen science and technology innovation commission
Lead Sponsor

Eligibility

Sex/Gender
All
Age
10 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Patients that pathological confirmed with nasopharyngeal carcinoma from ENT hospital of longgang district, shenzhen; 2. male or female, aged from 10 to 60 years old; 3. untreated by radiotherapy and chemotherapy; 4. healthy normal nasopharyngeal tissue control.

Exclusion criteria

Exclusion criteria: 1. Patients with renal insufficiency; 2. Pregnant or lactating women; 3. Those who were vaccinated within three months.

Design outcomes

Primary

MeasureTime frame
Protein expression in nasopharyngeal cancer tissue;—

Countries

China

Contacts

Public ContactZhiqiang Liu

Shenzhen Institute of ENT

liuzhiqiang05312438@126.com15986613913

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026